[2] 国家食品药品监督管理总局. 药品注册管理办法（局令第28号）[EB/OL]. 2007-10-01. http：//www.sda.gov.cn/WS01/CL0053/24529.html.
　　[3] 国家食品药品监督管理总局. 中药注册管理补充规定（国食药监注[2008]3号）[EB/OL]. 2008-01-07. http：//www.sda.gov.cn/WS01/CL0055/27432.html.
　　Common questions and suggestions of evaluation for NDA of TCM
　　MA Xiu-jing*， ZHANG Yong-wen， YANG Chang-ming
　　（Center for Drug Evaluation， State Food and Drug Administration， Beijing100038， China）
　　[Abstract]According to the existing Provisions for Drug Registration （SFDA Order No. 28）， applications for new drugs of traditional Chinese medicine are divided into two parts： the applications for drug clinical trial and for drug production （including new drug certificate）. It will last for about 10 years from the application for drug clinical trial to get approving， and it also remains many problems and the low probability to succeed. From the sight of pharmaceutical review， there are mainly two aspects of regulatory compliance and technical issues， mainly for changes without approval of the competent authorities of the country. For example， sample preparation and approval of clinical trial process are significant changes. Technical problems are reporting incomplete data or information submitted does not comply with the technical requirements for review， such as： production process validation does not provide information， the preparation of samples for clinical trials and field inspection， production information， or the information provided does not meet the technical requirements. This paper summarizes the frequently asked questions and to make recommendations to advise applicants concerned， timely detection of problems， avoid risk， improving the quality and efficiency of the application for registration.
　　[Key words]NDA； pharmaceutical review；common questions and suggestions
　　doi：10.4268/cjcmm20141739

(责任编辑：南粤论文中心)转贴于南粤论文中心: http://www.nylw.net(代写代发论文_毕业论文带写_广州职称论文代发_广州论文网）